Tokai Announces Oral Presentation on Galeterone at the 2016 AUA Annual Meeting

Tokai Pharmaceuticals Inc., a biopharmaceutical company focused on developing and commercializing innovative therapies for prostate cancer and other hormonally driven diseases, announced an oral presentation on galeterone at the 2016 American Urological Association (AUA) Annual Meeting in San Diego. Galeterone, Tokai’s lead product candidate, is being developed for the treatment of men with metastatic castration-resistant prostate cancer.  

The presentation, titled “Galeterone shows anti-tumor activity in multiple pre-clinical models that express androgen receptor splice variants, supporting correlative patient data seen in ARMOR2” (abstract number PD32-07), will be presented on Sunday, May 8, from 4:30 - 4:40 p.m. PDT in room 30DE, as part of the session, “Prostate Cancer: Advanced (including Drug Therapy) III.” The presenting author is Vincent C.O. Njar, Ph.D., Professor of Medicinal Chemistry and Pharmacology, Department of Pharmacology; Head of the Medicinal Chemistry Section, Center for Biomolecular Therapeutics; and Member of the Marlene and Stewart Greenebaum Cancer Center at the University of Maryland School of Medicine, Baltimore. Dr. Njar is a co-inventor of galeterone.  

About Galeterone

Galeterone is an oral small molecule that utilizes the established pathways, including CYP17 enzyme and androgen

receptor inhibition, of the current second-generation hormonal therapies abiraterone and enzalutamide. Galeterone also

introduces a distinct third mechanism – androgen receptor degradation – that decreases the sensitivity of androgen

receptors to androgen activity, thus leading to reductions in tumor growth. Tokai is developing galeterone for the treatment

of patients with metastatic castration-resistant prostate cancer (mCRPC). ARMOR3-SV, the company’s pivotal Phase 3

study of galeterone in treatment-naive mCRPC patients whose prostate tumors express the AR-V7 splice variant, is

evaluating whether administration of galeterone results in a statistically significant increase in radiographic progression-free

survival as compared to enzalutamide. Tokai is also evaluating galeterone in mCRPC patients who have shown resistance

following treatment with second-generation hormonal agents. Tokai has worldwide development and commercialization

rights to galeterone.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe